A sequence-activated AND logic dual-channel fluorescent probe for tracking programmable drug release

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Molecular Diagnostics

Background:

• Translating in vivo biomarker sensing into diagnostics and therapeutics is challenging.
• Eliminating false positive signals from logic gates is crucial for reliable applications.
• Tumor microenvironments present complex biological milieu requiring sophisticated sensing and release mechanisms.

Purpose of the Study:

• To develop a sense-of-logic dual-channel nanoprobe for programmable in vivo diagnostics and therapeutics.
• To implement a sequence-activated AND logic gate for ultra-sensitive and specific biomarker detection.
• To achieve controllable anti-cancer drug release triggered by specific tumor microenvironment cues.

Main Methods:

• Design of a dual-channel nanoprobe operating via a sequence-activated AND logic gate.
• Utilizing pH changes and biothiol as sequential triggers for drug release.
• Synchronizing programmable drug release with dual-channel near-infrared (NIR) fluorescence output.

Main Results:

• The nanoprobe demonstrated ultra-sensitive response to pH changes and subsequent triggering by biothiol.
• Programmable drug release was achieved in a multistage tumor microenvironment (acidic organelles and glutathione-overexpressing cytosol).
• The AND logic gate provided feedback on biological milieu complexity and enhanced tumor therapeutic efficiency through precise targeting.

Conclusions:

• The developed nanoprobe merges sensing and drug release capabilities with logical molecular design.
• The sequential AND logic gate enhances specificity and feedback on biological complexity.
• This approach significantly improves tumor therapeutic efficiency via precise targeting and programmable drug release.